$5.22
-0.13[-2.43%]
At close: Apr 25
$5.22
0[0.00%]
After Hours: 4:20PM EDT
Editas Medicine
(NASDAQ:EDIT)Editas Medicine Stock (NASDAQ:EDIT), Analyst Ratings, Price Targets, Predictions
Editas Medicine Inc has a consensus price target of $17.5, established from looking at the 58 latest analyst ratings. The last 3 analyst ratings were released from Citigroup, Barclays, and JP Morgan on February 29, 2024, February 29, 2024, and February 27, 2024. With an average price target of $12 between Citigroup, Barclays, and JP Morgan, there's an implied 129.89% upside for Editas Medicine Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Citigroup
Barclays
JP Morgan
Truist Securities
Cantor Fitzgerald
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Editas Medicine
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 02/29/2024 | EDIT | Buy Now | Editas Medicine | $5.22 | 206.51% | Citigroup | Samantha Semenkow | $11 → $16 | Maintains | Buy | Get Alert |
| 02/29/2024 | EDIT | Buy Now | Editas Medicine | $5.22 | 110.73% | Barclays | Gena Wang | $10 → $11 | Maintains | Equal-Weight | Get Alert |
| 02/27/2024 | EDIT | Buy Now | Editas Medicine | $5.22 | 72.41% | JP Morgan | Brian Cheng | $8 → $9 | Maintains | Neutral | Get Alert |
| 12/12/2023 | EDIT | Buy Now | Editas Medicine | $5.22 | 283.14% | Truist Securities | Joon Lee | $15 → $20 | Maintains | Buy | Get Alert |
| 10/24/2023 | EDIT | Buy Now | Editas Medicine | $5.22 | 110.73% | Citigroup | Samantha Semenkow | → $11 | Upgrade | Neutral → Buy | Get Alert |
| 10/18/2023 | EDIT | Buy Now | Editas Medicine | $5.22 | 53.26% | JP Morgan | Brian Cheng | → $8 | Upgrade | Underweight → Neutral | Get Alert |
| 10/17/2023 | EDIT | Buy Now | Editas Medicine | $5.22 | — | Cantor Fitzgerald | Eric Schmidt | — | Downgrade | Overweight → Neutral | Get Alert |
| 09/29/2023 | EDIT | Buy Now | Editas Medicine | $5.22 | 225.67% | Stifel | Dae Gon Ha | $9 → $17 | Upgrade | Hold → Buy | Get Alert |
| 09/13/2023 | EDIT | Buy Now | Editas Medicine | $5.22 | 168.2% | Cantor Fitzgerald | Rick Bienkowski | → $14 | Reiterates | Overweight → Overweight | Get Alert |
| 08/29/2023 | EDIT | Buy Now | Editas Medicine | $5.22 | 168.2% | Cantor Fitzgerald | Rick Bienkowski | → $14 | Reiterates | Overweight → Overweight | Get Alert |
| 08/03/2023 | EDIT | Buy Now | Editas Medicine | $5.22 | 129.89% | Oppenheimer | Jay Olson | → $12 | Reiterates | Perform → Perform | Get Alert |
| 08/03/2023 | EDIT | Buy Now | Editas Medicine | $5.22 | 263.98% | Chardan Capital | Geulah Livshits | $22 → $19 | Maintains | Buy | Get Alert |
| 06/13/2023 | EDIT | Buy Now | Editas Medicine | $5.22 | 187.36% | Cantor Fitzgerald | Rick Bienkowski | → $15 | Reiterates | Overweight → Overweight | Get Alert |
| 06/13/2023 | EDIT | Buy Now | Editas Medicine | $5.22 | 225.67% | Raymond James | Steven Seedhouse | → $17 | Upgrade | Market Perform → Outperform | Get Alert |
| 05/09/2023 | EDIT | Buy Now | Editas Medicine | $5.22 | 129.89% | Oppenheimer | Jay Olson | → $12 | Reiterates | → Perform | Get Alert |
| 05/08/2023 | EDIT | Buy Now | Editas Medicine | $5.22 | 53.26% | RBC Capital | Luca Issi | $7 → $8 | Maintains | Sector Perform | Get Alert |
| 05/08/2023 | EDIT | Buy Now | Editas Medicine | $5.22 | 168.2% | Credit Suisse | Richard Law | $15 → $14 | Maintains | Neutral | Get Alert |
| 05/08/2023 | EDIT | Buy Now | Editas Medicine | $5.22 | 321.46% | Chardan Capital | Geulah Livshits | → $22 | Reiterates | → Buy | Get Alert |
| 02/23/2023 | EDIT | Buy Now | Editas Medicine | $5.22 | 187.36% | Credit Suisse | Richard Law | $13 → $15 | Maintains | Neutral | Get Alert |
FAQ
What is the target price for Editas Medicine (EDIT)?
The latest price target for Editas Medicine (NASDAQ: EDIT) was reported by Citigroup on February 29, 2024. The analyst firm set a price target for $16.00 expecting EDIT to rise to within 12 months (a possible 206.51% upside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Editas Medicine (EDIT)?
The latest analyst rating for Editas Medicine (NASDAQ: EDIT) was provided by Citigroup, and Editas Medicine maintained their buy rating.
When was the last upgrade for Editas Medicine (EDIT)?
The last upgrade for Editas Medicine Inc happened on October 24, 2023 when Citigroup raised their price target to $11. Citigroup previously had a neutral for Editas Medicine Inc.
When was the last downgrade for Editas Medicine (EDIT)?
The last downgrade for Editas Medicine Inc happened on October 17, 2023 when Cantor Fitzgerald changed their price target from N/A to N/A for Editas Medicine Inc.
When is the next analyst rating going to be posted or updated for Editas Medicine (EDIT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Editas Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Editas Medicine was filed on February 29, 2024 so you should expect the next rating to be made available sometime around February 28, 2025.
Is the Analyst Rating Editas Medicine (EDIT) correct?
While ratings are subjective and will change, the latest Editas Medicine (EDIT) rating was a maintained with a price target of $11.00 to $16.00. The current price Editas Medicine (EDIT) is trading at is $5.22, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.